HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Edward D. Verrier Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Boyle, E. M. Articles by Verrier, E. D. Search for Related Content PubMed PubMed Citation Articles by Boyle, E. M., Jr Articles by Verrier, E. D.

Ann Thorac Surg 1997;63:277-284
© 1997 The Society of Thoracic Surgeons

---

Current Reviews

Endothelial Cell Injury in Cardiovascular Surgery: The Systemic Inflammatory Response

Division of Cardiothoracic Surgery, University of Washington, Seattle, Washington

	Abstract

Top Footnotes Abstract Introduction Systemic Endothelial Cell... Complement Mediated Endothelial... Prolonged Adhesion Molecule... Potential Therapeutic Options References

 
Many of the components currently used to perform cardiovascular operations lead to systemic insults that result from cardiopulmonary bypass circuit-induced contact activation, circulatory shock, and resuscitation, and a syndrome similar to endotoxemia. Experimental observations have demonstrated that these events have profound effects on activating endothelial cells to recruit neutrophils from the circulation. Once adherent to the endothelium, neutrophils release cytotoxic proteases and oxygen-derived free radicals, which are responsible for much of the end-organ damage seen after cardiovascular operations. Recently the cellular and molecular mechanisms of endothelial cell activation have become increasingly understood. It is conceivable that once the molecular mechanisms of endothelial cell activation are better defined, therapies will be developed allowing the selective or collective inhibition of vascular endothelial activation during the perioperative period.

	Introduction

Top Footnotes Abstract Introduction Systemic Endothelial Cell... Complement Mediated Endothelial... Prolonged Adhesion Molecule... Potential Therapeutic Options References

 

Inflammation in itself is not to be considered as a disease ... and in disease, where it can alter the diseased mode of action, it likewise leads to a cure; but where it cannot accomplish that salutary purpose, ... it does mischief.

John Hunter: Treatise on the Blood, Inflammation, and Gunshot Wounds, London, 1794

The English surgeon John Hunter first recognized the malignant systemic spread of inflammation as an abnormal response to injury two centuries ago. The early pioneers in cardiac surgery recognized a similar pattern of systemic injury they encountered after cardiopulmonary bypass (CPB). Kirklin [1] hypothesized that the deleterious effects of CPB were secondary to the exposure of blood to abnormal surfaces in the bypass circuit, which initiated a "whole body inflammatory response." He noted that this response is characterized by activation of coagulation, the kallikrein system, fibrinolysis, and complement, all of which are now recognized as the mediators of the disseminated intravascular post-pump syndrome [1, 2]. Further work has identified the presence of circulating inflammatory cytokines, also observed in the systemic inflammatory response syndromes associated with shock and sepsis [3, 4]. Experimental observations have demonstrated that these cytokines have a profound effect on activating endothelial cells to participate in the inflammatory response to injury [5]. The end result of the humoral cascading that is initiated by CPB includes widespread endothelial cell activation, which in turn, likely results in the diffuse expression of leukocyte adhesion molecules on surfaces of vascular endothelial cells. Once adherent to the endothelium, neutrophils release cytotoxic proteases and oxygen-derived free radicals that are responsible for much of the end-organ damage seen after cardiac operations. Further suggestion of neutrophil-mediated injury, which occurs not only from complement activation but from increased neutrophil-endothelial adhesion, comes from studies that demonstrate neutrophil-derived proteases in the circulation after CPB. These proteases break down elastin, collagen, and fibronectin, destroying extracellular structures, and contribute to the capillary leak that leads to extracellular volume overload and electrolyte imbalance in the postoperative period [6]. Although it is difficult to demonstrate in studies with small patient populations, there seems to be a correlation between high neutrophil degranulation products and systemic complement activation and multiple system organ failure after CPB [6].

In addition to the inflammatory interactions that result from the CPB circuit, cardiogenic shock can further contribute to inflammatory response of cardiac operations. Some patients experience varying degrees of cardiogenic shock during CPB, when coming off the pump, and when recovering from the operation. Prolonged nonpulsatile perfusion or periods of circulatory arrest can lead to diffuse end-organ ischemia as well [7]. The end organ hypoxic insult likely causes endothelial cells, circulating monocytes, and tissue-fixed macrophages to release cytokines and oxygen-derived free radicals that drive this response. Once the patient is resuscitated from shock and after hypoxic end organs are reperfused, a form of systemic ischemia-reperfusion injury results [8].

Still another form of inflammatory activation that results from extracorporeal circulation and episodes of systemic ischemia-reperfusion is endotoxemia (lipopolysaccharide). Endotoxin is frequently detected in high concentrations in the systemic circulation after CPB [9, 10]. Endotoxin is a potent stimulant not only of complement activation, but of endothelial cell activation resulting in the surface up-regulation of adherence molecules and tissue factor [11, 12]. Endotoxin is a potent agonist of macrophage tumor necrosis factor release, which may explain why the level of this cytokine is elevated in some patients after CPB. Although the mechanism of endotoxemia after CPB is unclear, this may derive from a translocation of bacteria from the gut, resulting from the systemic stress of CPB and splanchnic ischemia, coupled with impaired Kupffer cell function [13]. The result is a transient endotoxemia that contributes to the overall state of systemic inflammation after CPB.

Evidence that complement and cytokine cascades are involved in the pathologic inflammatory response to CPB has been reported in a number of studies that detail the presence and time course of circulating inflammatory elements as they appear in the bloodstream after the initiation of CPB. The most prominent early response is massive complement activation, heralded by a rapid increase in C5a and C3a, which appear in the blood that exits the extracorporeal circuit [2, 14]. C5a is a soluble by-product of complement activation. It serves as a marker for generalized complement activation, and itself causes capillary leak, neutrophil degranulation, and the expression of the neutrophil adhesion molecule P-selectin on the surfaces of platelets and the endothelium [15–17]. Cytokine release is also a prominent feature of the inflammatory response to CPB. Numerous investigators have detailed the presence and time course of circulating cytokines as they are released in response to CPB. Once bypass is initiated, levels of interleukin-1 (IL-1), tumor necrosis factor, IL-6, and IL-8 rapidly increase [18–22]. The degree of cytokine response appears to correlate with the length of CPB and aortic cross-clamp time [23]. What is largely unknown, however, is where these cytokines originate. Experiments using simulated extracorporeal circuits have demonstrated that complement is activated in the bypass circuit; however, the cytokine response does not resemble what is seen clinically [14]. Neutrophils, macrophages, and endothelial cells in culture release cytokines in response to injury [24, 25]. It is possible that the cytokine response results from activated endothelial cells, adherent neutrophils, and tissue-fixed macrophages, driven by complement activation and myocardial and systemic ischemia-reperfusion injury during the course of the operation.

The fact that many patients successfully recover from CPB, despite this massive inflammatory response, suggests that the individual responses to inflammatory stimuli vary from person to person. Furthermore, it attests to the body's tremendous physiologic reserve and sophisticated inhibitory pathways that prevent widespread organ damage after heart operations [1]. Recently, however, an increasing number of patients undergoing cardiac operations have a limited physiologic reserve. Neonates and infants as well as the elderly and those who require long CPB times are especially susceptible to systemic effects of endothelial cell injury [1]. As patients undergo operations in a worsening physiologic state it is increasingly important to seek improved understanding of the biological mechanisms of organ damage and new therapies to modulate the injury suffered after cardiac operations.

	Systemic Endothelial Cell Activation

Top Footnotes Abstract Introduction Systemic Endothelial Cell... Complement Mediated Endothelial... Prolonged Adhesion Molecule... Potential Therapeutic Options References

 
The vascular endothelium has a pivotal role in the systemic host response to injury and therefore, the systemic injury that follows CPB [26]. Central to the understanding of the endothelial injury after cardiac operation is the concept of endothelial cell activation. Under resting conditions the endothelial cell lining of blood vessels is a relatively inert surface that regulates the passage of intravascular substrates to the extravascular space and assures the unhindered flow of cellular and serum elements through the capillary beds. In response to inflammatory signals, such as cytokines, lipopolysaccharide, complement activation products (C5a), hypoxia, or oxygen-derived free radicals, endothelial cells are converted to an activated state, resulting in profound changes in gene expression and cellular function. Activated endothelial cells release cytokines and express proteins on their surface that promote inflammatory reactions and thrombosis [12, 27]. In the classic host response to injury, endothelial cell activation is beneficial in recruiting neutrophils and promoting coagulation to limit the local spread of infection. Although this response is extremely destructive, the limited area of collateral tissue injury is usually well tolerated on the local level. The host response is less well adapted to respond to injury on a systemic level. Cardiopulmonary bypass and other components of modern critical care have led to survival despite severe systemic illness and physiologic stresses that the human body probably never evolved to control. Therefore, after CPB, sepsis, or resuscitation from shock, well evolved local inflammatory responses to injury become manifested systemically with the release of cytokines, the activation of large areas of endothelium, and the margination and degranulation of neutrophils on a much larger scale. The feedback mechanisms that limit the destructive response locally appear to be less accurate on a systemic level, leading to an ineffective and overwhelming host response. This overwhelming response is evident after CPB, where evidence suggests that the activated vascular endothelial layer promotes widespread leukocyte adhesion molecule and tissue factor expression, mediating end-organ damage and consumption of coagulation factors that contributes to the coagulopathy that often complicates cardiac operations [28–33]. This is also evident in other syndromes of systemic inflammation, such as systemic inflammatory response syndrome, adult respiratory distress syndrome, and multiple system organ failure, where the host's response to injury actually contributes to further organ injury [3, 4, 24, 34].

Therefore, understanding the signals that result in endothelial activation is important in assessing potential therapies to block this response. The cellular and molecular mechanisms of endothelial cell activation have been elucidated in endothelial cells cultured from human umbilical veins [5]. The process of endothelial cell activation involves a complex series of cellular and molecular steps, each step representing a potential point of therapeutic control. There appears to be two phases of endothelial cell activation that contribute to organ dysfunction after CPB. In the first, the immediate phase, circulating complement degradation products initiate an immediate but short-lived neutrophil adhesive response. The second phase requires several hours to develop as new proteins, such as E-selectin, ICAM, and IL-8, are made and expressed by endothelial cell in response to exposure to circulating cytokines, lipopolysaccharide, and inflammatory mediators [35–38] (Fig 1).

View larger version (28K): [in this window] [in a new window]   Fig 1. . The disseminated intravascular postpump syndrome. (ICAM = intracellular adhesion molecule; IL = interleukin; TNF = tumor necrosis factor; VCAM = vascular cell adhesion molecule.)

	Complement Mediated Endothelial Cell Activation

Top Footnotes Abstract Introduction Systemic Endothelial Cell... Complement Mediated Endothelial... Prolonged Adhesion Molecule... Potential Therapeutic Options References

View larger version (16K): [in this window] [in a new window]   Fig 2. . The classic and alternative pathways of complement activation. The classic pathway requires an antigen-antibody complex to be formed. This occasionally happens when protamine is given to reverse heparin. The alternative pathway is nonspecific, and can be activated by foreign surfaces and the surface of endotoxin. When complement is activated, soluble factors, such as C5a and C3a, are released into the circulation.

	Prolonged Adhesion Molecule Expression

Top Footnotes Abstract Introduction Systemic Endothelial Cell... Complement Mediated Endothelial... Prolonged Adhesion Molecule... Potential Therapeutic Options References

 
Although it is likely that complement activation mediates the first and most immediate wave of leukocyte adherence molecule expression, both in vitro and in vivo studies reveal that this response is short lived [33, 46]. As the early phase of complement-mediated neutrophil adhesion wears off, a second wave develops as the other mediators of inflammation reach peak levels over the ensuing hours. Cytokine levels proportionately increase in direct response to the length of the procedure, activating endothelial cells throughout the body. Inflammatory mediators, such as cytokines or lipopolysaccharide, bind to specific receptors on the surface of the endothelium and stimulate the resting endothelium to convert to the activation state. Signals are transmitted through the cell wall, through a wide variety of second messenger systems, to signal transduction pathways that translocate to the nucleus to turn on a specific set of genes, known as the activation genes [47]. There are multiple stretches of DNA that make up the activation genes, which are transcribed as a result of endothelial cell activation. In the patient undergoing cardiovascular operation, the most significant are the genes that encode for E-selectin, ICAM, VCAM, IL-8, inducible nitric oxide synthase, and tissue factor.

A tremendous amount of information has recently emerged that details the molecular signaling pathways that lead to the transduction of extracellular signals to the regulatory regions controlling the genes that are activated in CPB patients. What is most notable is that this wide array of inflammatory signals appear to funnel through a single signal transduction pathway using the transcription factor NF-kB [48, 49]. NF-kB is a ubiquitous transcription factor involved in the regulation of genes that respond to various forms of external stimulation [47] (Fig 3). Once activated, NF-kB translocates to the nucleus where it binds with specific DNA sequences, altering conformation of the basal transcriptional apparatus, resulting in the transcription of the various activation genes. Usually NF-kB is bound to IkB, the cytosolic inhibitory protein that keeps NF-kB inactive [50]. When activated by cytokines, lipopolysaccharide, or hypoxia-reoxygenation, the NF-kB-IkB complex is phosphorylated, and the complex becomes dissociated. Once dissociated, IkB is degraded rapidly, and in parallel, there is an accumulation of NF-kB in the nucleus. This results in the initiation of transcription of the activation genes. The DNA of the activation genes transcribe specific message RNA transcripts that are then translated into proteins in the cytoplasm, modified, and later expressed on the cell surface or released into the local environment. This process takes about 4 hours and peaks at 8 to 24 hours, depending on the gene [36, 37]. In addition, when endothelial cells are activated, transcription of IkB is promoted, which feeds back to bind with NF-kB and thereby decrease levels of free NF-kB, subsequently shutting off expression of the NF-kB activated genes [50]. Thus, the release of IkB appears to be the central event required for the activation of NF-kB, and ultimately, for gene activation and syntheses of new proteins in response to extracellular stimuli.

View larger version (25K): [in this window] [in a new window]   Fig 3. . Signal transduction through NF-kB. (ICAM = intracellular adhesion molecule; IL-1 = interleukin-1; LPS = lipopolysaccharide; TNF = tumor necrosis factor.)

	Potential Therapeutic Options

Top Footnotes Abstract Introduction Systemic Endothelial Cell... Complement Mediated Endothelial... Prolonged Adhesion Molecule... Potential Therapeutic Options References

 
Techniques designed to impair neutrophil-endothelial cell interaction have the potential to attenuate the whole body inflammatory response to CPB. Having an impact on neutrophil-endothelial cell interaction can occur in a variety of ways. Because a majority of the inciting events begin as a result of the blood's interaction with the CPB circuit, efforts have been focused at altering the components of the extracorporeal oxygenator. The bubble oxygenator, especially when containing nylon mesh, was shown to result in a greater degree of complement activation and pulmonary leukosequestration prompting many surgeons to turn to membrane oxygenators [2, 51, 52]. Advances in biomedical engineering have led to the ability to coat CPB lines with heparin, which seems to increase the biocompatibility of the circuit and decrease complement activation [53–55]. Another available device is the Pall filter, which allows the removal of neutrophils from the circulation, decreasing their availability to promote inflammatory injury [52, 56]. Unfortunately leukocytes return to the circulation when the filter is discontinued. Although these techniques may appear helpful, their utility in clinical practice are as yet unproven [57].

There are a variety of additional techniques available to block neutrophil adhesion to the activated endothelium. Specific monoclonal antibodies were developed by cellular biologists as tools to identify adhesion molecules expressed on cytokine-activated endothelium. The exploitation of this advance as a therapeutic tool led not only to an improved understanding of the role of adhesion molecules but also to novel avenues to modulate this response. Today there are an increasing number of monoclonal antibodies available to block adhesion molecules before neutrophils can adhere. The objective of antiadhesion therapy after CPB should be to prevent neutrophil adherence during the first 24 hours after operation, thereby preventing the neutrophils from mediating widespread organ damage. In designing therapies to block this critical leukocyte-endothelial interaction, it is imperative to address the time courses of expression of specific endothelial adherence molecules so that interventions can be directed to each specific adhesion molecule at the time when it can be expected to be maximally expressed. Monoclonal antibodies blocking selectins (E-selectin, P-selectin), or circulating oligosaccharide antagonists that block the interaction of the neutrophil S lex ligand with endothelial selectins, prevent the rolling and subsequent adherence of neutrophils. Gillinov and associates [28] used the antiinflammatory agent NPC 15669 to inhibit neutrophil adhesion in a CPB model and found a marked decrease in pulmonary injury. Adhesion molecule blockade, however, increases susceptibility to infection, limiting that approach as a therapeutic strategy [58]. Furthermore, once the endothelial cell is activated it expresses a broad variety of surface adhesion proteins at different time intervals that would require a complex mixture of agents to effectively block the consequences of endothelial activation.

Rather than blocking the surface proteins after they are expressed, an alternative approach would be to block activation before adhesion molecules are made by endothelial cells. One of the simplest ways to block cellular machinery is with hypothermia. The time-tested technique of hypothermia is basically an attempt to shut down the cellular metabolic activity during ischemic cardiac arrest. The effects of hypothermia on endothelial function, however, have been minimally studied [59]. We investigated the effect of hypothermia on endothelial cell activation and found that although activation was temporarily halted below 25°C, as evidenced by E-selectin and tissue factor surface expression, NF-kB still accumulates in the nucleus until the cells rewarm, when transcription begins and activation continues unabated [60]. These findings have been corroborated clinically by Menasche and colleagues [61, 62] who found that hypothermia delays but does not prevent the expression of neutrophil adherence molecules. Therefore, although hypothermia is beneficial when the patient is cold, the benefits are rapidly lost when the patient rewarms.

Investigators are now examining the molecular signaling processes that regulate expression of individual adhesion molecules, many of which share similar signal transduction pathways. Studies of the molecular mechanisms promoting the expression of endothelial cell activation genes are of particular interest in the development of novel therapies to attenuate the organ dysfunction and coagulopathy sometimes seen after cardiac operations. Efforts to further characterize the molecular events that result endothelial cell activation after inflammation may allow the utilization of the growing number of gene-directed techniques to modulate and thereby prevent some of the inflammation and coagulopathy that frequently complicates cardiovascular operations. It is conceivable that once the molecular mechanisms of endothelial cell activation are better understood, therapies will be developed that will allow the selective or collective inhibition of vascular endothelial activation during the perioperative period, allowing patients to better tolerate cardiac operations.

	Footnotes

Top Footnotes Abstract Introduction Systemic Endothelial Cell... Complement Mediated Endothelial... Prolonged Adhesion Molecule... Potential Therapeutic Options References

 
Address reprint requests to Dr Verrier, Division of Cardiothoracic Surgery, University of Washington, 1959 Pacific St NE, Box 356310, Seattle, WA 98195 (e-mail: verriere{at}ctd.surgery.washington.edu).

	References

Top Footnotes Abstract Introduction Systemic Endothelial Cell... Complement Mediated Endothelial... Prolonged Adhesion Molecule... Potential Therapeutic Options References

 

1. Kirklin JK. Prospects for understanding and eliminating the deleterious effects of cardiopulmonary bypass. Ann Thorac Surg 1991;51:529–31.[Medline]
2. Chenoweth DE, Cooper SW, Hugli TE, et al. Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins. N Engl J Med 1981;304:497–503.[Abstract]
3. Beal AL, Cerra FB. Multiple organ failure syndrome in the 1990s: systemic inflammatory response and organ dysfunction. JAMA 1994;271:226–33.[Abstract/Free Full Text]
4. Carrico CJ, Meakins JL, Marshall JC, et al. Multiple organ failure syndrome. Arch Surg 1986;121:196–208.[Abstract/Free Full Text]
5. Pober JS, Cotran RS. Cytokines and endothelial cell biology. Physiol Rev 1990;70:427–51.[Free Full Text]
6. Faymonville ME, Pincemail J, Duchateau J, et al. Myeloperoxidase and elastase as markers of leukocyte activation during cardiopulmonary bypass in humans. J Thorac Cardiovasc Surg 1991;102:309–17.[Abstract]
7. Verrier ED, Shen I. Potential role of neutrophil anti-adhesion therapy in myocardial stunning, myocardial infarction, and organ dysfunction after cardiopulmonary bypass. J Cardiol Surg 1993;8:309–12.
8. Vedder NB, Winn RK, Rice CL, et al. Inhibition of leukocyte adherence by anti-CD18 monoclonal antibody attenuates reperfusion injury in the rabbit ear. Proc Natl Acad Sci USA 1990;87:2643–6.[Abstract/Free Full Text]
9. Knudsen F, Andersen LW. Immunological aspects of cardiopulmonary bypass. J Cardiothorac Anesth 1990;4:245–58.[Medline]
10. Nilsson L, Kulander L, Nystrom SO, Eriksson O. Endotoxins in cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990;100:777–80.[Abstract]
11. Pohlman TH, Harlan JM. Endotoxin-endothelial Interactions. In: Morrison DC, Ryan J, eds. Bacterial endotoxic lipopolysacchrides, Vol 1. Boca Raton: CRC Press, 1992:348–69.
12. Crossman DC, Tuddenham EDG. Procoagulant functions of the endothelium. In: Warren JB, ed. The endothelium: an introduction to current research. New York: Wiley-Liss, 1990:119–28.
13. Taggart DP, Sundaram S, McCartney C, et al. Endotoxemia, complement, and white blood cell activation in cardiac surgery: a randomized trial of laxatives and pulsatile perfusion. Ann Thorac Surg 1994;57:376–82.[Abstract]
14. Moat NE, Rebuck N, Shore DF, et al. Humoral and cellular activation in a simulated extracorporeal circuit. Ann Thorac Surg 1993;56:1509–14.[Abstract]
15. Wachtfogel YT, Kucich U, Greenplate J, et al. Human neutrophil degranulation during extracorporeal circulation. Blood 1987;69:324–30.[Abstract/Free Full Text]
16. Steinberg JB, Kapelanski DP, Olson JD, Weiler JM. Cytokine and complement levels in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1993;106:1008–16.[Abstract]
17. Foreman KE, Vaporciyan AA, Bonish BK, et al. C5a-induced expression of P-selectin in endothelial cells. J Clin Invest 1994;94:1147–55.
18. Frering B, Philip I, Dehoux M, et al. Circulating cytokines in patients undergoing normothermic cardiopulmonary bypass. J Thorac Cardiovasc Surg 1994;108:636–41.[Abstract/Free Full Text]
19. Casey LC. Role of cytokines in the pathogenesis of cardiopulmonary-induced multisystem organ failure. Ann Thorac Surg 1993;56:S92–6.
20. Kalfin RE, Engelman RM, Rousou JA, et al. Induction of interleukin-8 expression during cardiopulmonary bypass. Circulation 1993;88(Suppl 2):401–6.
21. Finn A, Naik S, Klein N, et al. Interleukin-8 release and neutrophil degranulation after pediatric cardiopulmonary bypass. J Thorac Cardiovasc Surg 1993;105:234–41.[Abstract]
22. Butler J, Rocker GM, Westaby S. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1993;55:552–9.[Abstract]
23. Hennein HA, Ebba H, Rodriguez JL, et al. Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. J Thorac Cardiovasc Surg 1994;108:626–35.[Abstract/Free Full Text]
24. Bankey PE, Hill S, Geldon D. Sequential insult enhances liver macrophage-stimulated hepatocyte dysfunction. J Surg Res 1994;57:185–91.[Medline]
25. Shreeniwas R, Koga S, Karakurum M, et al. Hypoxia-mediated induction of endothelial cell interleukin-1 alpha. An autocrine mechanism promoting expression of leukocyte adhesion molecules on the vessel surface. J Clin Invest 1992;90:2333–9.
26. Verrier ED. The vascular endothelium: friend or foe? Ann Thorac Surg 1993;55:818–9.[Medline]
27. Virkhaus R, Lucchesi BR, Simpson PJ, Shebuski RJ. The role of adhesion molecules in cardiovascular pharmacology: meeting review. J Pharmacol Exp Ther 1995;273:569–75.[Free Full Text]
28. Gillinov AM, Redmond JM, Zehr KJ, et al. Inhibition of neutrophil adhesion during cardiopulmonary bypass. Ann Thorac Surg 1994;57:126–33.[Abstract]
29. Gillinov AM, Bator JM, Zehr KJ, et al. Neutrophil adhesion molecule expression during cardiopulmonary bypass with bubble and membrane oxygenators. Ann Thorac Surg 1993;56:847–53.[Abstract]
30. Gillinov AM, Redmond JM, Winkelstein JA, et al. Complement and neutrophil activation during cardiopulmonary bypass: a study in the complement-deficient dog. Ann Thorac Surg 1994;57:345–52.[Abstract]
31. Kilbridge PM, Mayer JE, Newburger JW, et al. Induction of intercellular adhesion molecule-1 and E-selectin mRNA in heart and skeletal muscle of pediatric patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1994;107:1183–92.[Abstract/Free Full Text]
32. Wilson I, Gillinov AM, Curtis WE, et al. Inhibition of neutrophil adherence improves postischemic ventricular performance of the neonatal heart. Circulation 1993;88(Suppl 2):372–9.[Abstract/Free Full Text]
33. Burns SA, DeGuzman BJ, Newburger JW, et al. P-selectin expression in myocardium of children undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1995;110:924–33.[Abstract/Free Full Text]
34. Wilmore DW, Aulick LH, Mason AD, Pruitt BA. Influence of the burn wound on local and systemic responses to injury. Ann Surg 1978;196:444–58.
35. Nawroth PP, Handley DA, Esmon CT, Stern DM. Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity. Proc Natl Acad Sci USA 1986;83:3460–4.[Abstract/Free Full Text]
36. Montgomery KF, Osborn L, Hession C, et al. Activation of endothelial-leukocyte adhesion molecule 1 (ELAM-1) gene transcription. Proc Natl Acad Sci 1991;88:6523–7.[Abstract/Free Full Text]
37. Bevilacqua MP, Pober JS, Mendrick DL, et al. Identification of an inducible endothelial-leukocyte adhesion molecule. Proc Natl Acad Sci USA 1987;84:9238–42.[Abstract/Free Full Text]
38. Harlan J. Leukocyte-endothelial interactions. Blood 1985;65:513–25.[Free Full Text]
39. Kirklin JK, Westaby S, Blackstone EH, et al. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1983;86:845–57.[Abstract]
40. Cho PW, Gillinov AM, Zehr KJ, et al. Neutrophil activation mediates protamine-induced pulmonary hypertension. J Surg Res 1993;54:486–93.[Medline]
41. Atkinson JP, Farries T. Separation of self from non-self in the complement system. Immunol Today 1987;8:212–5.
42. Spiess BD. Introduction. J Cardiovasc Pharmacol 1996;27:v–vii.
43. Wagner DD. The Weibel-Palade body: the storage granule for von Willebrand factor and P-selectin. Thromb Haemost 1993;70:105–10.[Medline]
44. Rinder C, Fitch J. Amplification of the inflammatory response: adhesion molecules associated with platelet/white cell responses. J Cardiovasc Pharmacol 1996;27:S6–12.
45. Kilgore KS, Shen JP, Miller BF, et al. Enhancement by complement membrane attack complex of tumor necrosis factor induced endothelial cell expression of E-selectin and ICAM-1. J Immunol 1995;155:1434–41.[Abstract]
46. Lorant DE, Topham MK, Whatley RE, et al. Inflammatory roles of P-selectin. J Clin Invest 1993;92:559–70.
47. Thanos D, Maniatis T. NF-kB: a lesson in family values. Cell 1995;80:529–32.[Medline]
48. Karin M. Signal transduction from cell surface to nucleus in development and disease. FASEB J 1992;8:2581–90.
49. Magnuson DK, Maier RV, Pohlman TH. Protein kinase C: a potential pathway of endothelial cell activation by endotoxin, tumor necrosis factor, and interleukin-1. Surgery 1989;106:216–23.[Medline]
50. Collins T, Read MA, Neish AS, et al. Transcriptional regulation of endothelial cell adhesion molecules: NF-kB and cytokine-inducible enhancers. FASEB J 1995;9:899–909.[Abstract]
51. Nilsson L, Tyd'en H, Johansson O, et al. Bubble and membrane oxygenators-comparison of postoperative organ dysfunction with special reference to inflammatory activity. Scand J Thorac Cardiovasc Surg 1990;24:59–64.[Medline]
52. Gu YJ, Obster R, Haan J, et al. Biocompatibility of leukocyte removal filters during leukocyte filtration of cardiopulmonary bypass perfusate. Artif Organs 1993;17:660–5.[Medline]
53. Fosse E, Moen O, Johnson E, et al. Reduced complement and granulocyte activation with heparin-coated cardiopulmonary bypass. Ann Thorac Surg 1994;58:472–7.[Abstract]
54. Gu YJ, van-Oeveren W, Akkerman C, et al. Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1993;55:917–22.[Abstract]
55. Jones DR, Hill RC, Hollingsed MJ, et al. Use of heparin-coated cardiopulmonary bypass. Ann Thorac Surg 1993;56:566–8.[Abstract]
56. Wilson IC, Gardner TJ, DiNatale JM, et al. Temporary leukocyte depletion reduces ventricular dysfunction during prolonged postischemic reperfusion. J Thorac Cardiovasc Surg 1993;106:805–10.[Abstract]
57. Cameron D. Initiation of white cell activation during cardiopulmonary bypass: cytokines and receptors. J Cardiovasc Pharmacol 1996;27:S1–5.
58. Sharar SR, Winn RK, Murry CE, et al. A CD18 monoclonal antibody increases the incidence and severity of subcutaneous abscess formation after high-dose Staphylococcus aureus injection in rabbits. Surgery 1991;110:213–9.[Medline]
59. Hansen T, Dawson P, Brockbank K. Effects of hypothermia upon endothelial cells: mechanisms and clinical importance. Cryobiology 1994;31:101–6.[Medline]
60. Johnson M, Haddix T, Pohlman T, Verrier ED. Hypothermia reversibly inhibits endothelial cell expression of E-selectin and tissue factor. J Cardiol Surg 1995;10:428–35.
61. Menasche P, Peynet J, Haeffner-Cavallion N, et al. Influence of temperature on neutrophil trafficking during clinical cardiopulmonary bypass. Circulation 1995;92(Suppl 2):334–40.[Abstract/Free Full Text]
62. Le Deist F, Menasche P, Kucharski C, et al. Hypothermia during cardiopulmonary bypass delays but does not prevent neutrophil-endothelial cell adhesion: a clinical study. Circulation 1995;92(Suppl 2):354–8.[Abstract/Free Full Text]

This article has been cited by other articles:

				F. Onorati, G. Santarpino, G. Tangredi, G. Palmieri, A. S. Rubino, D. Foti, E. Gulletta, and A. Renzulli Intra-aortic balloon pump induced pulsatile perfusion reduces endothelial activation and inflammatory response following cardiopulmonary bypass Eur. J. Cardiothorac. Surg., June 1, 2009; 35(6): 1012 - 1019. [Abstract] [Full Text] [PDF]

				X. Sun, L. Zhang, P. C. Hill, R. Lowery, A. T. Lee, R. E. Molyneaux, P. J. Corso, and S. W. Boyce Is incidence of postoperative vasoplegic syndrome different between off-pump and on-pump coronary artery bypass grafting surgery? Eur. J. Cardiothorac. Surg., October 1, 2008; 34(4): 820 - 825. [Abstract] [Full Text] [PDF]

				J. McGuinness, J. Byrne, C. Condron, J. McCarthy, D. Bouchier-Hayes, and J. M. Redmond Pretreatment with {omega}-3 fatty acid infusion to prevent leukocyte-endothelial injury responses seen in cardiac surgery J. Thorac. Cardiovasc. Surg., July 1, 2008; 136(1): 135 - 141. [Abstract] [Full Text] [PDF]

				E. B. Savage, R. S. Farivar, and E. J. Okum Cardiac Surgical Physiology Card. Surg. Adult, January 1, 2008; 3(2008): 51 - 76. [Full Text]

				J. S. Savino and A. T. Cheung Cardiac Anesthesia Card. Surg. Adult, January 1, 2008; 3(2008): 281 - 314. [Full Text]

				A. A. Amirghofran and A. Emami Nia Right Heart Operations Without Cardiopulmonary Bypass: The Use of Temporary Total Cavopulmonary Connection Ann. Thorac. Surg., October 1, 2007; 84(4): 1414 - 1415. [Abstract] [Full Text] [PDF]

				M. Egi, R. Bellomo, C. Langenberg, M. Haase, A. Haase, L. Doolan, G. Matalanis, S. Seevenayagam, and B. Buxton Selecting a Vasopressor Drug for Vasoplegic Shock After Adult Cardiac Surgery: A Systematic Literature Review Ann. Thorac. Surg., February 1, 2007; 83(2): 715 - 723. [Abstract] [Full Text] [PDF]

				V. Anttila, I. Hagino, Y. Iwata, B. A. Mettler, H. G.W. Lidov, D. Zurakowski, and R. A. Jonas Aprotinin improves cerebral protection: Evidence from a survival porcine model J. Thorac. Cardiovasc. Surg., October 1, 2006; 132(4): 948 - 953. [Abstract] [Full Text] [PDF]

				T. Modine, R. Azzaoui, T. Ouk, G. Fayad, D. Lacroix, H. Warembourg, R. Bordet, and T. Gourlay Changes in Cerebral Vascular Reactivity Occur Early During Cardiopulmonary Bypass in the Rat Ann. Thorac. Surg., August 1, 2006; 82(2): 672 - 678. [Abstract] [Full Text] [PDF]

				D. J. Kozik and J. S. Tweddell Characterizing the Inflammatory Response to Cardiopulmonary Bypass in Children Ann. Thorac. Surg., June 1, 2006; 81(6): S2347 - S2354. [Abstract] [Full Text] [PDF]

				G. Shanmugam Vasoplegic syndrome--the role of methylene blue Eur. J. Cardiothorac. Surg., November 1, 2005; 28(5): 705 - 710. [Abstract] [Full Text] [PDF]

				M. Kamler, J. Goedeke, N. Pizanis, V. Milekhin, F.-U. Schade, and H. Jakob In vivo effects of hypothermia on the microcirculation during extracorporeal circulation Eur. J. Cardiothorac. Surg., August 1, 2005; 28(2): 259 - 265. [Abstract] [Full Text] [PDF]

				Y. Lamarche, O. Malo, E. Thorin, A. Denault, M. Carrier, J. Roy, and L.P. Perrault Inhaled but not intravenous milrinone prevents pulmonary endothelial dysfunction after cardiopulmonary bypass J. Thorac. Cardiovasc. Surg., July 1, 2005; 130(1): 83 - 92. [Abstract] [Full Text] [PDF]

				E. Iriz, F. Kolbakir, H. Akar, B. Adam, and H. T. Keceligil Comparison of Hydroxyethyl Starch and Ringer Lactate as a Prime Solution Regarding S-100{beta} Protein Levels and Informative Cognitive Tests in Cerebral Injury Ann. Thorac. Surg., February 1, 2005; 79(2): 666 - 671. [Abstract] [Full Text] [PDF]

				B. G. Loef, R. H. Henning, A. H. Epema, G. W. Rietman, W. van Oeveren, G. J. Navis, and T. Ebels Effect of dexamethasone on perioperative renal function impairment during cardiac surgery with cardiopulmonary bypass Br. J. Anaesth., December 1, 2004; 93(6): 793 - 798. [Abstract] [Full Text] [PDF]

				A. S. Aharon, M. R. Mulloy, D. C. Drinkwater Jr, O. B. Lao, M. D. Johnson, M. Thunder, C. Yu, and P. Chang Cerebral activation of mitogen-activated protein kinases after circulatory arrest and low flow cardiopulmonary bypass Eur. J. Cardiothorac. Surg., November 1, 2004; 26(5): 912 - 919. [Abstract] [Full Text] [PDF]

				J. Boldt, C. Brosch, A. Lehmann, S. Suttner, and F. Isgro The Prophylactic Use of the {beta}-Blocker Esmolol in Combination with Phosphodiesterase III Inhibitor Enoximone in Elderly Cardiac Surgery Patients Anesth. Analg., October 1, 2004; 99(4): 1009 - 1017. [Abstract] [Full Text] [PDF]

				R. V. Plachinta, M. J. M. de Klaver, J. K. Hayes, and G. F. Rich The Protective Effect of Protein Kinase C and Adenosine Triphosphate-Sensitive Potassium Channel Agonists Against Inflammation in Rat Endothelium and Vascular Smooth Muscle In Vitro and In Vivo Anesth. Analg., August 1, 2004; 99(2): 556 - 561. [Abstract] [Full Text] [PDF]

				S. Fortier, R.G. DeMaria, Y. Lamarche, O. Malo, A. Denault, F. Desjardins, M. Carrier, and L.P. Perrault Inhaled prostacyclin reduces cardiopulmonary bypass-induced pulmonary endothelial dysfunction via increased cyclic adenosine monophosphate levels J. Thorac. Cardiovasc. Surg., July 1, 2004; 128(1): 109 - 116. [Abstract] [Full Text] [PDF]

				B. Wei, Y. Liu, Q. Wang, C. Yu, C. Long, Y. Chang, and Y. Ruan Lung perfusion with protective solution relieves lung injury in corrections of Tetralogy of Fallot Ann. Thorac. Surg., March 1, 2004; 77(3): 918 - 924. [Abstract] [Full Text] [PDF]

				D. L. Ngaage Off-pump coronary artery bypass grafting: the myth, the logic and the science Eur. J. Cardiothorac. Surg., October 1, 2003; 24(4): 557 - 570. [Abstract] [Full Text] [PDF]

				A. J. Chong, C. R. Hampton, and E. D. Verrier Microvascular Inflammatory Response in Cardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2003; 7(3): 333 - 354. [Abstract] [PDF]

				R. Gerrah, Y. Shargal, and A. Elami Impaired oxygenation and increased hemolysis after cardiopulmonary bypass in patients with glucose-6-phosphate dehydrogenase deficiency Ann. Thorac. Surg., August 1, 2003; 76(2): 523 - 527. [Abstract] [Full Text] [PDF]

				R. G. Leyh, T. Kofidis, M. Struber, S. Fischer, K. Knobloch, B. Wachsmann, C. Hagl, A. R. Simon, and A. Haverich Methylene blue: The drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass? J. Thorac. Cardiovasc. Surg., June 1, 2003; 125(6): 1426 - 1431. [Abstract] [Full Text] [PDF]

				E. Jensen, S. Andreasson, A. Bengtsson, H. Berggren, R. Ekroth, L. Lindholm, and J. Ouchterlony Influence of two different perfusion systems on inflammatory response in pediatric heart surgery Ann. Thorac. Surg., March 1, 2003; 75(3): 919 - 925. [Abstract] [Full Text] [PDF]

				A. J. Chong, T. H. Pohlman, C. R. Hampton, A. Shimamoto, N. Mackman, and E. D. Verrier Tissue factor and thrombin mediate myocardial ischemia-reperfusion injury Ann. Thorac. Surg., February 1, 2003; 75(2): S649 - 655. [Abstract] [Full Text] [PDF]

				S. Muraki, C. D. Morris, J. M. Budde, Z.-Q. Zhao, R. A. Guyton, and J. Vinten-Johansen Blood cardioplegia supplementation with the sodium-hydrogen ion exchange inhibitor cariporide to attenuate infarct size and coronary artery endothelial dysfunction after severe regional ischemia in a canine model J. Thorac. Cardiovasc. Surg., January 1, 2003; 125(1): 155 - 164. [Abstract] [Full Text] [PDF]

				J. Vinten-Johansen, Z.-Q. Zhao, and R. A. Guyton Cardiac Surgical Physiology Card. Surg. Adult, January 1, 2003; 2(2003): 53 - 84. [Full Text]

				J. S. Savino, T. F. Floyd, and A. T. Cheung Cardiac Anesthesia Card. Surg. Adult, January 1, 2003; 2(2003): 249 - 281. [Full Text]

				M. P. Vallely, P. G. Bannon, C. F. Hughes, and L. Kritharides Endothelial expression of intercellular adhesion molecule 1 and vascular cell adhesion molecule 1 is suppressed by postbypass plasma containing increased soluble intercellular adhesion molecule 1 and vascular cell adhesion molecule 1 J. Thorac. Cardiovasc. Surg., October 1, 2002; 124(4): 758 - 767. [Abstract] [Full Text] [PDF]

				M. A. Ozatik, O. Tarcan, A. Kale, G. Askon, M. Balco, A. Undar, D. S. Kucukaksu, E. Sener, and O. Tasdemir Do S100{beta} protein level increases due to inflammation during cardiopulmonary bypass occur without any neurological deficit? Perfusion, September 1, 2002; 17(5): 335 - 338. [Abstract] [PDF]

				A. J. Rassias, A. L. Givan, C. A. S. Marrin, K. Whalen, J. Pahl, and M. P. Yeager Insulin Increases Neutrophil Count and Phagocytic Capacity After Cardiac Surgery Anesth. Analg., May 1, 2002; 94(5): 1113 - 1119. [Abstract] [Full Text] [PDF]

				O. M. Frass, F. Buhling, M. Tager, H. Frass, S. Ansorge, C. Huth, and T. Welte Antioxidant and Antiprotease Status in Peripheral Blood and BAL Fluid After Cardiopulmonary Bypass Chest, November 1, 2001; 120(5): 1599 - 1608. [Abstract] [Full Text] [PDF]

				J. C. Cleveland Jr, A. L. W. Shroyer, A. Y. Chen, E. Peterson, and F. L. Grover Off-pump coronary artery bypass grafting decreases risk-adjusted mortality and morbidity Ann. Thorac. Surg., October 1, 2001; 72(4): 1282 - 1289. [Abstract] [Full Text] [PDF]

				D. J. Campbell, B. Dixon, A. Kladis, M. Kemme, and J. D. Santamaria Activation of the kallikrein-kinin system by cardiopulmonary bypass in humans Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2001; 281(4): R1059 - R1070. [Abstract] [Full Text] [PDF]

				D. A. Velez, C. D. Morris, J. M. Budde, S. Muraki, R. N. Otto, R. A. Guyton, and J. Vinten-Johansen All-Blood (Miniplegia) Versus Dilute Cardioplegia in Experimental Surgical Revascularization of Evolving Infarction Circulation, September 18, 2001; 104 (2009): I-296 - I-302. [Abstract] [Full Text] [PDF]

				A. Mekontso-Dessap, R. Houel, C. Soustelle, M. Kirsch, D. Thebert, and D. Y. Loisance Risk factors for post-cardiopulmonary bypass vasoplegia in patients with preserved left ventricular function Ann. Thorac. Surg., May 1, 2001; 71(5): 1428 - 1432. [Abstract] [Full Text] [PDF]

				L B Mongero, J R Beck, H E Manspeizer, E J Heyer, K Lee, T A Spanier, and C R Smith Cardiac surgical patients exposed to heparin-bonded circuits develop less postoperative cerebral dysfunction than patients exposed to non-heparin-bonded circuits Perfusion, March 1, 2001; 16(2): 107 - 111. [Abstract] [PDF]

				C. F. Mojcik and J. H. Levy Aprotinin and the systemic inflammatory response after cardiopulmonary bypass Ann. Thorac. Surg., February 1, 2001; 71(2): 745 - 754. [Abstract] [Full Text] [PDF]

				A O Chukwuemeka, M R. Turtle, U H Trivedi, G E Venn, and D J Chambers A clinical evaluation of platelet function, haemolysis and oxygen transfer during cardiopulmonary bypass comparing the Quantum HF-6700 to the HF-5700 hollow fibre membrane oxygenator Perfusion, December 1, 2000; 15(6): 479 - 484. [Abstract] [PDF]

				R. D. Riley, H. Sato, Z.-Q. Zhao, V. H. Thourani, J. E. Jordan, A. X. Fernandez, X.-L. Ma, D. R. Hite, D. F. Rigel, T. C. Pellas, et al. Recombinant human complement C5a receptor antagonist reduces infarct size after surgical revascularization J. Thorac. Cardiovasc. Surg., August 1, 2000; 120(2): 350 - 358. [Abstract] [Full Text] [PDF]

				M. S. Ali, M. Harmer, and R. Vaughan Serum S100 protein as a marker of cerebral damage during cardiac surgery Br. J. Anaesth., August 1, 2000; 85(2): 287 - 298. [Abstract] [Full Text] [PDF]

				M. Czerny, H. Baumer, J. Kilo, A. Lassnigg, A. Hamwi, T. Vukovich, E. Wolner, and M. Grimm Inflammatory response and myocardial injury following coronary artery bypass grafting with or without cardiopulmonary bypass Eur. J. Cardiothorac. Surg., June 1, 2000; 17(6): 737 - 742. [Abstract] [Full Text] [PDF]

				R. A. Bronicki, C. L. Backer, H. P. Baden, C. Mavroudis, S. E. Crawford, and T. P. Green Dexamethasone reduces the inflammatory response to cardiopulmonary bypass in children Ann. Thorac. Surg., May 1, 2000; 69(5): 1490 - 1495. [Abstract] [Full Text] [PDF]

				W. A. Cooper, I. G. Duarte, V. H. Thourani, M. Nakamura, N.-P. Wang, W. M. Brown III, J. P. Gott, J. Vinten-Johansen, and R. A. Guyton Hypothermic circulatory arrest causes multisystem vascular endothelial dysfunction and apoptosis Ann. Thorac. Surg., March 1, 2000; 69(3): 696 - 702. [Abstract] [Full Text] [PDF]

				A. O. Halldorsson, M. T. Kronon, B. S. Allen, S. Rahman, and T. Wang Lowering reperfusion pressure reduces the injury after pulmonary ischemia Ann. Thorac. Surg., January 1, 2000; 69(1): 198 - 203. [Abstract] [Full Text] [PDF]

				M. T. Kronon, B. S. Allen, A. Halldorsson, S. Rahman, T. Wang, and M. Ilbawi DOSE DEPENDENCY OF L-ARGININE IN NEONATAL MYOCARDIAL PROTECTION: THE NITRIC OXIDE PARADOX J. Thorac. Cardiovasc. Surg., October 1, 1999; 118(4): 655 - 664. [Abstract] [Full Text] [PDF]

				J. C. Kovacich, E. M. Boyle Jr, E. N. Morgan, T. G. Canty Jr, A. L. Farr, M. T. Caps, N. Frank, T. H. Pohlman, and E. D. Verrier INHIBITION OF THE TRANSCRIPTIONAL ACTIVATOR PROTEIN NUCLEAR FACTOR {kappa}BPREVENTS HEMODYNAMIC INSTABILITY ASSOCIATED WITH THE WHOLE-BODY INFLAMMATORYRESPONSE SYNDROME J. Thorac. Cardiovasc. Surg., July 1, 1999; 118(1): 154 - 162. [Abstract] [Full Text] [PDF]

				U. Boeken, P. Feindt, N. Zimmermann, G. Kalweit, T. Petzold, and E. Gams Increased preoperative C-reactive protein (CRP)-values without signs of an infection and complicated course after cardiopulmonary bypass (CPB) - operations Eur. J. Cardiothorac. Surg., May 1, 1999; 13(5): 541 - 545. [Abstract] [Full Text] [PDF]

				C. Baufreton, L. Intrator, P. G.M. Jansen, H. te Velthuis, P. Le Besnerais, A. Vonk, J.-P. Farcet, C. R.H. Wildevuur, and D. Y. Loisance Inflammatory response to cardiopulmonary bypass using roller or centrifugal pumps Ann. Thorac. Surg., April 1, 1999; 67(4): 972 - 977. [Abstract] [Full Text] [PDF]

				C. Baufreton, M. Kirsch, and D. Y. Loisance Measures to control blood activation during assisted circulation Ann. Thorac. Surg., November 1, 1998; 66(5): 1837 - 1844. [Abstract] [Full Text] [PDF]

				L. Lindberg, A-K. Olsson, K. Anderson, and P. Jogi SERUM S-100 PROTEIN LEVELS AFTER PEDIATRIC CARDIAC OPERATIONS: A POSSIBLE NEW MARKER FOR POSTPERFUSION CEREBRAL INJURY J. Thorac. Cardiovasc. Surg., August 1, 1998; 116(2): 281 - 285. [Abstract] [Full Text] [PDF]

				A. Halldorsson, M. Kronon, B. S. Allen, K. S. Bolling, T. Wang, S. Rahman, H. Feinberg, and R. S. Hartz Controlled Reperfusion After Lung Ischemia: Implications For Improved Function After Lung Transplantation J. Thorac. Cardiovasc. Surg., February 1, 1998; 115(2): 415 - 425. [Abstract] [Full Text] [PDF]

				A. K. Alameddine and T. J. Vander Salm Lower Limb Ischemia With Compartment Syndrome Related to Femoral Artery Cannulas Ann. Thorac. Surg., September 1, 1997; 64(3): 884 - 885. [Full Text]

This Article Abstract Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Edward D. Verrier Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Boyle, E. M. Articles by Verrier, E. D. Search for Related Content PubMed PubMed Citation Articles by Boyle, E. M., Jr Articles by Verrier, E. D.